Tolerance profiles and immunosuppression
Alberto Sanchez‐Fueyo – 23 September 2013
Therapeutic vaccination of a liver transplant recipient suffering from fulminant hepatitis B during pregnancy
Adalbert Krawczyk, Hedwig Roggendorf, Charlotte Ludwig, Kerstin Herzer, Guido Gerken, Peter A. Horn, Michael Roggendorf, Monika Lindemann – 23 September 2013
Transmission of dengue virus from a donor to a recipient after living donor liver transplantation
Sanjiv Saigal, Narendra S. Choudhary, Neeraj Saraf, Sushila Kataria, Ravi Mohanka, Arvinder S. Soin – 23 September 2013
Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease
Michel Blé, Victoria Aguilera, Angel Rubín, María García‐Eliz, Carmen Vinaixa, Martín Prieto, Marina Berenguer – 23 September 2013 – Hepatitis C virus (HCV) is associated with renal complications. We aimed to determine whether a sustained virological response (SVR) was associated with improvements in renal function (RF) in liver transplant (LT) recipients treated for HCV. Changes in RF were compared 1, 3, and 5 years after therapy as a function of the stage of chronic kidney disease (CKD) before treatment (BT).
Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation
Henry C. Lin, Luis Alvarez, Greggy Laroche, Hector Melin‐Aldana, Kim Pfeifer, Kathleen Schwarz, Peter F. Whitington, Estella M. Alonso, Udeme D. Ekong – 23 September 2013 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) results from recessive mutations in the adenosine triphosphate–binding cassette B11 gene, which encodes for bile salt export pump (BSEP). Liver transplantation (LT) is offered to PFIC2 patients with end‐stage liver disease.
Is disease recurrence still relevant to graft survival?
James F. Trotter – 23 September 2013
Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy
Neil Mehta, Jennifer L. Dodge, Aparna Goel, John Paul Roberts, Ryutaro Hirose, Francis Y. Yao – 23 September 2013 – It has been shown that patients with hepatocellular carcinoma (HCC) meeting the United Network for Organ Sharing T2 (Milan) criteria have an advantage in comparison with patients without HCC under the current organ allocation system for liver transplantation (LT). We hypothesized that within the T2 HCC group, there is a subgroup with a low risk of wait‐list dropout that should not receive the same listing priority.
Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation
Robert W. Krell, Daniel R. Kaul, Andrew R. Martin, Michael J. Englesbe, Christopher J. Sonnenday, Shijie Cai, Preeti N. Malani – 23 September 2013 – Although sarcopenia (muscle loss) is associated with increased mortality after liver transplantation, its influence on other complications is less well understood. We examined the association between sarcopenia and the risk of severe posttransplant infections among adult liver transplant recipients. By calculating the total psoas area (TPA) on preoperative computed tomography scans, we assessed sarcopenia among 207 liver transplant recipients.
Will retransplantation be the norm for pediatric recipients with ambitions for grandparenthood?
Deirdre A. Kelly – 23 September 2013
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients
Luca Quagliata, Matthias S. Matter, Salvatore Piscuoglio, Leila Arabi, Christian Ruiz, Alfredo Procino, Michal Kovac, Francesca Moretti, Zuzanna Makowska, Tujana Boldanova, Jesper B. Andersen, Monika Hämmerle, Luigi Tornillo, Markus H. Heim, Sven Diederichs, Clemente Cillo, Luigi M. Terracciano – 20 September 2013 – Hepatocellular carcinoma (HCC) is among the leading causes of cancer‐related death. Despite the advances in diagnosis and management of HCC, the biology of this tumor remains poorly understood.